AbTx develops next-gen ADCs using our TheranoStick platform, generating smaller formats (FDCs) for improved tumor access, faster clearance, and enhanced cytotoxicity. Our enzymatic conjugation (transglutaminase + patented Q-Tag system) ensures site-specific payload attachment across full-length antibodies, Fabs, scFvs, and VHHs, boosting efficacy and safety.

There is a great need for novel ADC payloads with a different mode of action. Novel payloads can be used to treat ADC-resistant patients and expand patient populations. This talk will show the discovery of a novel PLK1/BET degrader payload and its application in a TROP2-targeting degrader antibody conjugate with excellent in vivo activity and a differentiating and mild toxicity profile.

Antibody drug conjugates (ADCs) have shown clinical benefit across cancers, but resistance to topoisomerase and microtubule inhibitor payloads limits durable responses. Hexagon Bio is leveraging its natural product discovery platform to identify ADC payloads with novel, non-overlapping mechanisms of action and to evaluate rational combinations that may drive deeper, more durable efficacy. Hexagon Bio's first payload targets translation. Upcoming data will highlight efficacy, activity in resistant settings and a favorable non-human primate safety profile for its HER2-targeting ADC, alongside progress across a broader payload pipeline and combination strategies.

Developing ADCs with novel payloads will be critical to differentiate new assets in the clinic and allow for sequencing in the evolving treatment landscape. We will be describing a new ADC payload platform with a novel mode of action for enhanced utility in previously treated and resistant or refractory cancer patients. We will establish protein alkylation as a differentiated, next-generation payload modality with the potential to overcome resistance and expand the ADC therapeutic window, and showcase the preclinical profile of IKS073, a B7H3–targeting ProAlk ADC with potent anti-tumor activity and a compelling efficacy–tolerability balance across solid tumor models.